Category Archives: Uncategorized

Below, we are re-publishing with permission the press-release issued by BetaGlue Technologies on July 11, 2022 BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, is glad to announce that the first patient has been treated in a clinical … Continue reading →

Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Verve Medical, to conduct an early human feasibility study of their novel medical device for patients with treatment-resistant hypertension. World-wide, there … Continue reading →

Below, we are re-publishing with permission the press-release issued by InterVene, Inc. on December 13, 2021 December 13, 2021 07:00 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVene Inc. announced today that it has received Breakthrough Device Designation by … Continue reading →

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human trial of the coronary everolimus … Continue reading →

ContraBand™ technology helps restore the heart’s functionality and may significantly improve patients’ quality of life OR YEHUDA, Israel, Dec. 7, 2021 /PRNewswire/ — Restore Medical Ltd., a clinical-stage MedTech company developing cardiac implants for the treatment of congestive heart failure (CHF), today announced promising … Continue reading →

Clinical Accelerator is proud to have sponsored the CSI Focus D-HF (Device therapies in heart failure) conference this year in Frankfurt, Germany. Organized by Dr Horst Sievert, the two-day conference was one of the first to be in person in … Continue reading →

Anteris Technologies CEO talks ‘outstanding results’ from first human DurAVR patients

  Clinical Accelerator has recently entered into a new collaboration with CroíValve – a medical device company from Ireland – who is developing a novel, easy to use percutaneous solution for treating patients with severe Tricuspid Regurgitation (TR). Tricuspid Regurgitation … Continue reading →

Below, we are re-publishing with permission the press-release issued by VisCardia Inc. on April 23, 2020 PORTLAND, Ore., April 23, 2020 (Newswire.com) – VisCardia Inc., a privately held medical device developer, announced today it has been granted Breakthrough Device Designation … Continue reading →